Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. 2007

Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
The First Department of Internal Medicine, Kansai Medical University, 10-15, Fumizono-Cho, Moriguchi-City, Osaka, 570-8507, Japan.

A recent report revealed that a large population of Hodgkin's lymphoma-infiltrating lymphocytes (HLILs) consisted of regulatory T cells. In this study, we cocultured CD4+ naive T cells with KM-H2, which was established as a Hodgkin's Reed-Sternberg cell line, to clarify their ability to induce CD25+ Forkhead box P3+ (Foxp3+) T cells. The characteristic analyses of T cells cocultured with KM-H2 revealed the presence of CD4+CD25+ T cells. They expressed CTLA-4, glucocorticoid-induced TNFR family-related gene, and Foxp3 and could produce large amounts of IL-10. Conversely, KM-H2 also generated CD4+ CTLs, which expressed Granzyme B and T cell intracellular antigen-1 in addition to Foxp3+ T cells. They exhibit a strong cytotoxic effect against the parental KM-H2. In conclusion, KM-H2 promotes a bidirectional differentiation of CD4+ naive T cells toward Foxp3+ T cells and CD4+ CTLs. In addition to KM-H2, several cell lines that exhibit the APC function were able to generate Foxp3+ T cells and CD4+ CTLs. Conversely, the APC nonfunctioning cell lines examined did not induce both types of cells. Our findings suggest that the APC function of tumor cells is essential for the differentiation of CD4+ naive T cells into CD25+Foxp3+ T cells and CD4+ CTLs and at least partly explains the predominance of CD25+Foxp3+ T cells in HLILs and their contribution to a better prognosis. Therefore, in APC-functioning tumors, including classical Hodgkin lymphomas, which generate Foxp3+ T cells and CD4+ CTLs, these T cell repertories play a beneficial role synergistically in disease stability.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D014161 Transduction, Genetic The transfer of bacterial DNA by phages from an infected bacterium to another bacterium. This also refers to the transfer of genes into eukaryotic cells by viruses. This naturally occurring process is routinely employed as a GENE TRANSFER TECHNIQUE. Genetic Transduction,Genetic Transductions,Transductions, Genetic
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D016539 Reed-Sternberg Cells Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE. Sternberg-Reed Cells,Cells, Reed-Sternberg,Cells, Sternberg-Reed,Reed Sternberg Cells,Sternberg Reed Cells
D016753 Interleukin-10 A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein. IL-10,CSIF-10,Cytokine Synthesis Inhibitory Factor,IL10,Interleukin 10

Related Publications

Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
May 2008, Journal of leukocyte biology,
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
September 2011, International immunology,
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
June 2006, Journal of immunology (Baltimore, Md. : 1950),
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
January 2010, Pediatric endocrinology, diabetes, and metabolism,
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
December 1974, The New England journal of medicine,
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
January 2023, Nucleosides, nucleotides & nucleic acids,
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
August 2008, Journal of leukocyte biology,
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
November 1985, Journal of clinical pathology,
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
November 2012, Journal of leukocyte biology,
Tsutomu Tanijiri, and Toshiki Shimizu, and Kazutaka Uehira, and Takashi Yokoi, and Hideki Amuro, and Hiroyuki Sugimoto, and Yoshitaro Torii, and Kenichirou Tajima, and Tomoki Ito, and Ryuichi Amakawa, and Shirou Fukuhara
December 2003, The Journal of experimental medicine,
Copied contents to your clipboard!